Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict ß-coronaviral infection and replication.
Virology
; 569: 13-28, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1740261
ABSTRACT
Emerging mutations in the SARS-CoV-2 genome pose a challenge for vaccine development and antiviral therapy. The antiviral efficacy of Azadirachta indica bark extract (NBE) was assessed against SARS-CoV-2 and m-CoV-RSA59 infection. Effects of in vivo intranasal or oral NBE administration on viral load, inflammatory response, and histopathological changes were assessed in m-CoV-RSA59-infection. NBE administered inhibits SARS-CoV-2 and m-CoV-RSA59 infection and replication in vitro, reducing Envelope and Nucleocapsid gene expression. NBE ameliorates neuroinflammation and hepatitis in vivo by restricting viral replication and spread. Isolated fractions of NBE enriched in Nimbin isomers shows potent inhibition of m-CoV-RSA59 infection in vitro. In silico studies revealed that NBE could target Spike and RdRp of m-CoV and SARS-CoV-2 with high affinity. NBE has a triterpenoids origin that may allow them to competitively target panoply of viral proteins to inhibit mouse and different strains of human coronavirus infections, suggesting its potential as an antiviral against pan-ß-Coronaviruses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Azadirachta
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Virology
Year:
2022
Document Type:
Article
Affiliation country:
J.virol.2022.01.002
Similar
MEDLINE
...
LILACS
LIS